From Signal to Certainty: Why COPD Needs More Than One Trial

Area of Science:

• Regulatory Science
• Clinical Trial Design
• Pulmonology

Background:

• The U.S. Food and Drug Administration (FDA) proposes a single randomized controlled trial (RCT) as the default standard for drug approval.
• This shift challenges traditional regulatory philosophy, necessitating evaluation for complex diseases.

Purpose of the Study:

• To assess the suitability of a single RCT as the primary evidentiary standard for drug approval in chronic obstructive pulmonary disease (COPD).
• To explore concerns regarding the application of a single RCT standard to heterogeneous conditions like COPD.

Main Methods:

• Analysis of the implications of a single RCT standard for drug approval in COPD.
• Review of current limitations in mechanistic science, biomarkers, and statistical methods for COPD.
• Discussion of a conceptual regulatory framework for single RCT acceptance and alternative validation strategies.

Main Results:

• A single RCT poses risks for COPD due to disease heterogeneity, variable trajectories, modest treatment effects, and limited biomarkers.
• Reliance on one trial can increase inferential fragility, risk Type I errors, and reduce generalizability.
• Biomarker and trait-based strategies are promising but require further validation for robust treatment effect estimation.

Conclusions:

• For heterogeneous conditions like COPD, at least two independent studies are preferable to a single RCT for drug approval.
• A single RCT may be acceptable only under strict criteria (large effect size, biological plausibility, low bias, consistent subgroups).
• Post-marketing validation is essential if a single RCT is used, balancing patient access with evidentiary reliability.